{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Chronic Kidney Diseases",
            "NStudiesAvail": 430108,
            "NStudiesFound": 22,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 22,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "LaTonya Hickson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention",
                              "Blood serum estimated glomerular filtration rate (eGFR) reported in milliliters per minute (mL/min)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events and/or serious adverse events",
                              "Change in eGFR Value"
                        ],
                        "NCTId": [
                              "NCT05362786"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "LaTonya Hickson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2026"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events and/or serious adverse events"
                        ],
                        "NCTId": [
                              "NCT04869761"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Kim Hyosang"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint is an adverse event, and the level of the adverse event (AE) is analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)"
                        ],
                        "NCTId": [
                              "NCT05042206"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "GANG XU"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 30, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "GFR decrease at 2.5ml/min/year or more from baseline",
                              "To observe the incidence of serious adverse events\uff0csuch as fatal cardiovascular and cerebrovascular disease, tumor, organ failure, severe infection.",
                              "Collecting and comparing the number and severity of participants with skin reactions, fever, infection, allergic reactions, etc. in the two groups."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change of GFR",
                              "Incidence of Treatment-Serious Adverse Events as assessed by SPSS 23.0 and Graphpad prism 6",
                              "Number of participants with treatment-related adverse events as assessed by SPSS 23.0 and Graphpad prism 6"
                        ],
                        "NCTId": [
                              "NCT05512988"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Dong Sun, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "intravenous blood sampling"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "serum creatinine"
                        ],
                        "NCTId": [
                              "NCT03321942"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Hamid Gourabi, PhD",
                              "Nasser Aghdami, MD,PhD",
                              "Atieh Makhlough, MD",
                              "Reza Moghadasali, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation the probability of mass formation in patients with PKD after mesenchyma l stem cell transplantation."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Mass formation"
                        ],
                        "NCTId": [
                              "NCT02166489"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Hamid Gourabi, PhD",
                              "Nasser Aghdami, MD,PhD",
                              "Atieh Makhloogh, MD",
                              "Reza Moghadasali, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation the probability of mass formation due to MSC transplantation 6 months after cell injection.",
                              "Evaluation the rise of creatinin 1 month after cell transplantation."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "mass formation",
                              "Creatinin"
                        ],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Chadwick Prodromos, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Clinical monitoring of possible adverse events or complications"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety (adverse events)"
                        ],
                        "NCTId": [
                              "NCT05018845"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "LaTonya J Hickson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Enrolling by invitation"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Assessment of senescence markers in skin, fat, and/or blood at baseline and day 14."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in proportion of senescent cells (representing the total senescent cell burden) present"
                        ],
                        "NCTId": [
                              "NCT02848131"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "LaTonya J Hickson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To examine the effect of study drug (compared to placebo) on markers of inflammation in skin, fat, plasma, and urine measured at baseline and day 14",
                              "To examine the effect of study drug (compared to placebo) on mesenchymal stem cell function and vitality measured at baseline and day 14"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in inflammatory markers including C-reactive protein",
                              "Effect on Mesenchymal stem cell function including cell migration"
                        ],
                        "NCTId": [
                              "NCT03325322"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Tang Xun, doctor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The serum creatine elevation should be tested for at least 4 times, as follows, before treatment, 4 weeks after treatment, 8 weeks after treatment, 12 weeks after treatment.",
                              "The percentage of end-stage renal disease or death should be less than 60%."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The change of serum creatinine elevation",
                              "The percentage of end-stage renal disease or death."
                        ],
                        "NCTId": [
                              "NCT02966717"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Prof. Dr. Md. Firoj Khan, MBBS,FRCP,MD",
                              "Dr. Mohammed Yakub Ali MBBS, MPhil, MSc, PhD",
                              "Dr. Jahangir Md. Sarwar, MBBS, FCPS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 31, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Minor adverse events (MAEs):\n\nPain from lipo-suction > 7 days (Early)\nFever > 7 days (Early)\nSubcutaneous hematoma / abscess formation (Early)\nAllergic reaction (Immediate)\n\nSerious adverse events (SAEs)\n\nAnaphylaxis (Immediate)\nPulmonary embolism or infarction (Immediate)\nOutset of any neoplastic change (Late)\nOutset of new Cardiovascular events (Late)\nOutset of new Cerebrovascular or neurological events (Late)\nReactivation of treated tuberculosis (Late)",
                              "GFR with split renal function will be evaluated using DTPA Renogram.",
                              "eGFR will be calculated by Serum Creatinine level using MRDR formula during all visits.",
                              "Need for dialysis is described as\n\nNo dialysis needed - Score 0\nRandomly (more than 6 days interval) - Score 1\nAt 6 (six) days interval / Once weekly - Score 2\nAt 5 (five) days interval - Score 3\nAt 4 (four) days interval - Score 4\nAt 3 (three) days interval / 2 times a week - Score 5\nAt 2 (two) days interval - Score 6\nAt 1 (one) day interval / every alternate day./ 3 times a week - Score 7"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I",
                              "Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II",
                              "Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II",
                              "Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II"
                        ],
                        "NCTId": [
                              "NCT03939741"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Laetitia KOPPE, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "High throughput sequencing will be used to compare USC (Urinary Stem Cells) for the differential expression of genes between the 4 populations (obese or lean patients, with or without alteration of the kidney function). A gene set enrichment analysis will be used to identify the main functions supported by USC from each patient, establishing a signature."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Comparison of gene expression in USC (Urinary Stem Cells)"
                        ],
                        "NCTId": [
                              "NCT04998461"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Ningning Wang, Professor",
                              "Jiayin Liu, Professor",
                              "Lianju Qin"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 17, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The Bates-Jensen Wound Assessment (BWAT) is a standardized tool for quantitative assessment of wound healing that includes the 13 items listed below: (1)Size; (2)Depth; (3)Edges; (4)Undermining or pockets; (5)Necrotic tissue type; (6)Necrotic tissue amount; (7)Exudate type; (8)Exudate amount; (9)Surrounding skin color; (10)Peripheral tissue edema; (11)Peripheral tissue induration; (12)Granulation tissue; (13)Epithelialization.\n\nEach item was rated on a scale of 1 (best) to 5 (worst). The BWAT total score is the sum of the individual items with a possible range of 13 (best) to 65 (worst)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Wound Healing"
                        ],
                        "NCTId": [
                              "NCT04592640"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Jianming Tan T Jianming, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2008"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Creatinine and creatinine clearance rate"
                        ],
                        "NCTId": [
                              "NCT00659620"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Stephen C Textor, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 25, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Renal Tissue oxygenation",
                              "Number of patients with tissue injury markers"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Kidney function",
                              "Safety of Mesenchymal stem cell infusion"
                        ],
                        "NCTId": [
                              "NCT02266394"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Stephen Textor, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Individual kidney blood flow, measured by multidetector CT contrast transit times, will be measured before and after MSC infusion."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Renal blood flow and function in the treated kidneys."
                        ],
                        "NCTId": [
                              "NCT01840540"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 25, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The number of Adverse Events associated with UC-MSCs intervention per treatment arm",
                              "The percentage of Adverse Events associated with UC-MSCs intervention per treatment arm"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse Events",
                              "Adverse Events"
                        ],
                        "NCTId": [
                              "NCT04562025"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The patient's discomfort and clinical symptoms during the study were recorded, as well as the related laboratory test indicators and physical examination abnormalities of the subjects during the study.Describe the association with umbilical cord mesenchymal stem cell therapy and calculate the incidence of treatment-related acute and chronic adverse events."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient"
                        ],
                        "NCTId": [
                              "NCT04125329"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "LaTonya J Hickson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The number of Adverse Events associated with MSC intervention per treatment arm",
                              "The percentage of Adverse Events associated with MSC intervention per treatment arm"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse Events",
                              "Adverse Events"
                        ],
                        "NCTId": [
                              "NCT03840343"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 1, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Each participant was asked to indicate his or her current level of pain on a100 mm scale.\n\n0 mm indcates no pain and 100mm indicates the worst pain imaginable."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change from baseline in pain on the visual analogu scale at end of treatment"
                        ],
                        "NCTId": [
                              "NCT05276895"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Albert Hakaim, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluate the safety of AMSC administration by assessing the number of participants to experience an adverse event as defined by inflammation, infection (local or systemic), aneurysm formation, clinically significant increase or decrease in blood flow or thrombosis formation as evaluated through physical exam and ultrasound."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with treatment-related adverse events"
                        ],
                        "NCTId": [
                              "NCT04392206"
                        ]
                  }
            ]
      }
}